Jaguar Animal Health Announces Positive Results of Investigator-Initiated Follow-up Neonorm Study in Foals
This six-day, multi-site study (ARG102) involved 20 foals suffering from
secretory, or watery, diarrhea, all of which were placed into one
treatment group. During the treatment period, which lasted 72 hours,
Neonorm™ Foal was administered orally, in paste formulation,
twice daily for six treatments. In this study, a non-enteric form of
Neonorm™ Foal was used. The treatment period was followed by
a 72-hour observation period. Fecal scoring was conducted every six
hours during both the treatment and observation periods. The study took
As Jaguar announced last month, the Company completed an initial
proof-of-concept study (NEO101) of Neonorm™ Foal in
During the 72-hour treatment period, 35% of placebo-treated foals in NEO101 were identified as clinical responders, compared with 85% of foals treated with Neonorm™ Foal in ARG102. For the purposes of both studies, clinical responders were defined as foals that achieved a formed stool by the end of the reported period.
During the 72-hour treatment period, resolution of diarrhea was observed in 41% of placebo-treated foals in NEO101 compared with 85% of foals treated with Neonorm™ Foal in ARG102. For the purposes of both studies, resolution of diarrhea was defined as a foal that produced a formed stool at any point during the reported period.
Jaguar conducted a soft launch of Neonorm™ Foal at the
Diarrhea is one of the most common clinical complaints in foals, especially within the first 30 days of life, and to the Company’s knowledge there are currently no commercially available products with anti-secretory properties for foals. The crippling effects of dehydration that often occur as a result of secretory diarrhea in foals can manifest quickly, precipitate adverse health effects and result in death.
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s assumption that omitting enteric coating will meaningfully reduce the manufacturing costs of Neonorm™ Foal, the Company’s intention to develop species-specific formulations of Neonorm™ in additional target species, and the Company’s plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.